Epithelial-mesenchymal transition contributes to docetaxel resistance in human non-small cell lung cancer

Oncology Research

Volumn 22, Issue 1, 2014, Pages 47-55

  Shen, Weiwei ^a   Pang, Hailin ^a   Liu, Jiayu ^a   Zhou, Jing ^a   Zhang, Feng ^a   Liu, Lele ^a   Ma, Ningqiang ^a   Zhang, Ning ^a   Zhang, Helong ^a   Liu, Lili ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Docetaxel; Drug resistance; Epithelial mesenchymal transition (EMT); Human non small cell lung cancer

Indexed keywords

DOCETAXEL; FIBRONECTIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BAX; PROTEIN BCL 2; TRANSFORMING GROWTH FACTOR BETA; TUBULIN; UVOMORULIN; VIMENTIN; CADHERIN; MULTIDRUG RESISTANCE PROTEIN; TAXOID; TUMOR MARKER;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRUCTURE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; MULTIDRUG RESISTANCE; NON SMALL CELL LUNG CANCER; RESISTANCE INDEX; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL GROWTH; DRUG RESISTANCE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BIOMARKERS, TUMOR; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FIBRONECTINS; HUMANS; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS; TRANSFORMING GROWTH FACTOR BETA; TUBULIN; VIMENTIN;

EID: 84911214245     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504014X14098532393473     Document Type: Article

References (27)

1. Wilson, T. R.; Longley, D. B.; Johnston, P. G. Chemoresistance in solid tumours. Ann. Oncol. 17(Suppl. 10): x315-24; 2006.
2. Thiery, J. P.; Sleeman, J. P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7:131-42; 2006.
3. DiMeo, T. A.; Anderson, K.; Phadke, P.; Fan, C.; Perou, C. M.; Naber, S.; Kuperwasser, C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 69:5364-73; 2009.
4. Kudo-Saito, C.; Shirako, H.; Takeuchi, T.; Kawakami, Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15:195-206; 2009.
5. Tsuji, T.; Ibaragi, S.; Hu, G. F. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res. 69:7135-9; 2009.
6. Fuchs, B. C.; Fujii, T.; Dorfman, J. D.; Goodwin, J. M.; Zhu, A. X.; Lanuti, M.; Tanabe, K. K. Epithelial-tomesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res. 68:2391-9; 2008.
7. Christiansen, J. J.; Rajasekaran, A. K. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 66:8319-26; 2006.
8. Cheng, G. Z.; Chan, J.; Wang, Q.; Zhang, W.; Sun, C. D.; Wang, L. H. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 67:1979-87; 2007.
9. Li, Q. Q.; Xu, J. D.; Wang, W. J.; Cao, X. X.; Chen, Q.; Tang, F.; Chen, Z. Q.; Liu, X. P.; Xu, Z. D. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin. Cancer Res. 15:2657-65; 2009.
10. Li, Y.; VandenBoom, T. N.; Kong, D.; Wang, Z.; Ali, S.; Philip, P. A.; Sarkar, F. H. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-tomesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 69:6704-12; 2009.
11. Maseki, S.; Ijichi, K.; Tanaka, H.; Fujii, M.; Hasegawa, Y.; Ogawa, T.; Murakami, S.; Kondo, E.; Nakanishi, H. Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3beta/snail signalling pathway. Br. J. Cancer 106:1196-204; 2012.
12. Chang, T. H.; Tsai, M. F.; Su, K. Y.; Wu, S. G.; Huang, C. P.; Yu, S. L.; Yu, Y. L.; Lan, C. C.; Yang, C. H.; Lin, S. B.; Wu, C. P.; Shih, J. Y.; Yang, P. C. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am. J. Respir. Crit. Care Med. 183:1071-9; 2011.
13. McConkey, D. J.; Choi, W.; Marquis, L.; Martin, F.; Williams, M. B.; Shah, J.; Svatek, R.; Das, A.; Adam, L.; Kamat, A.; Siefker-Radtke, A.; Dinney, C. Role of epithelial-tomesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 28:335-44; 2009.
14. Sabbah, M.; Emami, S.; Redeuilh, G.; Julien, S.; Prevost, G.; Zimber, A.; Ouelaa, R.; Bracke, M.; De Wever, O.; Gespach, C. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist. Updates 11:123-51; 2008.
15. Saxena, M.; Stephens, M. A.; Pathak, H.; Rangarajan, A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2:e179; 2011.
16. Vega, S.; Morales, A. V.; Ocana, O. H.; Valdes, F.; Fabregat, I.; Nieto, M. A. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 18:1131-43; 2004.
17. Wu, Y.; Zhou, B. P. New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim. Biophys. Sin (Shanghai). 40:643-50; 2008.
18. Ren, J.; Chen, Y.; Song, H.; Chen, L.; Wang, R. Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxelresistant human lung adenocarcinoma cell line. J. Cell Biochem. 114:1395-403; 2013.
19. Reed, J. C.; Miyashita, T.; Takayama, S.; Wang, H. G.; Sato, T.; Krajewski, S.; Aime-Sempe, C.; Bodrug, S.; Kitada, S.; Hanada, M. BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell Biochem. 60:23-32; 1996.
20. Zhang, L.; Yu, J.; Park, B. H.; Kinzler, K. W.; Vogelstein, B. Role of BAX in the apoptotic response to anticancer agents. Science 290:989-92; 2000.
21. Calatozzolo, C.; Gelati, M.; Ciusani, E.; Sciacca, F. L.; Pollo, B.; Cajola, L.; Marras, C.; Silvani, A.; Vitellaro-Zuccarello, L.; Croci, D.; Boiardi, A.; Salmaggi, A. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J. Neurooncol. 74:113-21; 2005.
22. He, L.; Yang, C. P.; Horwitz, S.B. Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol. Cancer Ther. 1:3-10; 2001.
23. Mehta, R. S.; Bornstein, R.; Yu, I. R.; Parker, R. J.; McLaren, C. E.; Nguyen, K. P.; Li, K. T.; Fruehauf, J. P. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res. Treat. 66:225-37; 2001.
24. Loizzi, V.; Chan, J. K.; Osann, K.; Cappuccini, F.; DiSaia, P. J; Berman, M. L. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am. J. Obstet. Gynecol. 189:1301-7; 2003.
25. Holloway, R. W.; Mehta, R. S.; Finkler, N. J.; Li, K. T.; McLaren, C. E.; Parker, R. J.; Fruehauf, J. P. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol. Oncol. 87:8-16; 2002.
26. D'Amato, T. A.; Landreneau, R. J.; McKenna, R. J.; Santos, R. S.; Parker, R. J. Prevalence of in vitro extreme chemotherapy resistance in resected non small-cell lung cancer. Ann. Thorac. Surg. 81:440-6, 446-7; 2006.
27. Kern, D. H.; Weisenthal, L. M. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J. Natl. Cancer. Inst. 82:582-8; 1990.